Tsubota Lab ＜4890＞ announced on the 22nd that it will cancel the exclusive licensing rights relating to TLG-005 Parkinson's disease with Sumitomo Pharma ＜4506＞.

The company and Sumitomo Pharma have been proceeding with discussions for future commercialization studies based on the results of non-clinical research on TLG-005 Parkinson's disease and specific clinical research conducted by the company. No serious adverse events occurred in specific clinical studies, and certain effects were confirmed with respect to treatment effects, but since Sumitomo Pharma determined that it was difficult to calculate business value based only on the results of this specific clinical study, an agreement was reached that dissolving exclusive licensing rights at this stage would contribute to the future of both companies.

As a future research policy, the company will receive these results on TLG-005 Parkinson's disease and proceed with negotiations with the aim of partnering with new global companies in the future. Meanwhile, regarding TLG-005 depression and mild cognitive impairment, it is said that joint research with Sumitomo Pharma will continue to be examined.